JCJacek Capala

Jacek Capala

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jacek Capala has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Gabriela Kramer-Marek

    Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK

    8 shared publications
  • C. Norman Coleman

    Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    4 shared publications
  • Bhadrasain Vikram

    Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

    3 shared publications
  • Deepa Narayanan

    Small Business Innovation Research Development Center, National Cancer Institute, Bethesda, USA

    3 shared publications
  • Ilya Lyakhov

    Protein Chemistry Laboratory, SAIC-Frederick, Inc., NCI-Frederick, Frederick, MD

    3 shared publications
  • Oleg Chertov

    Protein Chemistry Laboratory, SAIC‐Frederick, Inc. NCI‐Frederick, Frederick, Maryland 21702 (USA)

    3 shared publications

Latest Publications

  • Neutron Capture Therapy: The Promise of Novel Agents and Medical Facility-Based Neutron Sources

    by Jacek Capala, Julie A. Hong, Bhadrasain Vikram, C. Norman Coleman

    Cancer Biotherapy & Radiopharmaceuticals


  • National Cancer Institute support for targeted alpha-emitter therapy

    by Julie A. Hong, Martin Brechbiel, Jeff Buchsbaum, Christie A. Canaria, C. Norman Coleman, Freddy E. Escorcia, Michael Espey, Charles Kunos, Frank Lin, Deepa Narayanan, et al.

    Background Radiopharmaceutical targeted therapy (RPT) has been studied for decades; however, recent clinical trials demonstrating efficacy have helped renewed interest in the modality. Methods This article reviews National Cancer Institute (NCI)’s support of RPT through communication via workshops and interest groups, through funding extramural programs in academia and small business, and through intramural research, including preclinical and clinical studies. Results NCI has co-organized workshops and organized interest groups on RPT and RPT dosimetry to encourage the community and facilitate rigorous preclinical and clinical studies. NCI has been supporting RPT research through various mechanisms. Research has been funded through peer-reviewed NCI Research and Program Grants (RPG) and NCI Small Business Innovation Research (SBIR) Development Center, which funds small business-initiated projects, some of which have led to clinical trials. The NCI Cancer Therapy Evaluation Program (CTEP)’s Radiopharmaceutical Development Initiative supports RPT in NCI-funded clinical trials, including Imaging and Radiation Oncology Core (IROC) expertise in imaging QA and dosimetry procedures. Preclinical targeted a-emitter therapy (TAT) research at the NCI’s intramural program is ongoing, building on foundational work dating back to the 1980s. Ongoing “bench-to-bedside” efforts leverage the unique infrastructure of the National Institutes of Health’s (NIH) Clinical Center. Conclusion Given the great potential of RPT, our goal is to continue to encourage its development that will generate the high-quality evidence needed to bring this multidisciplinary treatment to patients.


  • Open Access

    National Cancer Institute Support for Targeted Alpha-Emitter Therapy

    by Julie Hong, Martin Brechbiel, Jeff Buchsbaum, Christie A. Canaria, C. Norman Coleman, Freddy E. Escorcia, Michael Espey, Charles Kunos, Frank Lin, Deepa Narayanan, et al.

    Radiopharmaceutical targeted therapy (RPT) has been studied for decades, however, recent clinical trials demonstrating efficacy has helped renew interest in the modality. Recognizing the potential, the National Cancer Institute (NCI) has co-organized workshops and organized interest groups on RPT and RPT dosimetry to encourage the community and facilitate rigorous preclinical and clinical studies. NCI has been supporting RPT research through various mechanisms. Research has been funded through peer reviewed NCI Research and Program Grants (RPG) and NCI Small Business Innovation Research (SBIR) Development Center, which funds small business-initiated projects, some of which have led to clinical trials. The NCI Cancer Therapy Evaluation Program (CTEP)’s Radiopharmaceutical Development Initiative supports RPT in NCI-funded clinical trials, including Imaging and Radiation Oncology Core (IROC) expertise in imaging QA and dosimetry procedures. Preclinical targeted a-emitter therapy (TAT) research at the NCI’s intramural program is ongoing, building on foundational work dating back to the 1980s. Ongoing “Bench-to-bedside” efforts leverage the unique infrastructure of the National Institutes of Health’s (NIH) Clinical Center. Given the great potential of RPT, our goal is to continue to encourage its development that will generate the high quality evidence needed to bring this multidisciplinary treatment to patients.


  • Open Access

    Moving Forward in the Next Decade: Radiation Oncology Sciences for Patient-Centered Cancer Care

    by C Norman Coleman, Jeffrey C Buchsbaum, Pataje G S Prasanna, Jacek Capala, Ceferino Obcemea, Michael G Espey, Mansoor M Ahmed, Julie A Hong, Bhadrasain Vikram

    In a time of rapid advances in science and technology, the opportunities for radiation oncology are undergoing transformational change. The linkage between and understanding of the physical dose and induced biological perturbations are opening entirely new areas of application. The ability to define anatomic extent of disease and the elucidation of the biology of metastases has brought a key role for radiation oncology for treating metastatic disease. That radiation can stimulate and suppress subpopulations of the immune response makes radiation a key participant in cancer immunotherapy. Targeted radiopharmaceutical therapy delivers radiation systemically with radionuclides and carrier molecules selected for their physical, chemical, and biochemical properties. Radiation oncology usage of “big data” and machine learning and artificial intelligence adds the opportunity to markedly change the workflow for clinical practice while physically targeting and adapting radiation fields in real time. Future precision targeting requires multidimensional understanding of the imaging, underlying biology, and anatomical relationship among tissues for radiation as spatial and temporal “focused biology.” Other means of energy delivery are available as are agents that can be activated by radiation with increasing ability to target treatments. With broad applicability of radiation in cancer treatment, radiation therapy is a necessity for effective cancer care, opening a career path for global health serving the medically underserved in geographically isolated populations as a substantial societal contribution addressing health disparities. Understanding risk and mitigation of radiation injury make it an important discipline for and beyond cancer care including energy policy, space exploration, national security, and global partnerships.


  • A New Generation of “Magic Bullets” for Molecular Targeting of Cancer

    by Jacek Capala, Charles A. Kunos

    A two-step molecular targeting approach involving a self-assembling and disassembling (SADA) bispecific antibody platform and DOTA-radioconjugates allows tumor-specific delivery of diagnostic and therapeutic payloads. Low immunogenicity and the modular nature of SADA allow its optimization to safely and repeatedly deliver a variety of payloads to tumors expressing diverse tumor-specific antigens. See related article by Santich et al., p. 532


  • Open Access

    Radiopharmaceutical Switch Maintenance for Relapsed Ovarian Carcinoma

    by Charles A. Kunos, Jacek Capala

    Switch maintenance, or using alternative therapeutic agents that were not administered during a prior course of cancer treatment, has emerged as an active clinical research and regulatory agency-approvable path in the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) drug-development sequence. To better inform the design of therapeutic radiopharmaceutical trials, we reviewed academic scholarship discussing the clinical use of maintenance approaches to cancer treatment. Women with advanced-stage primary platinum-refractory or platinum-resistant ovarian carcinoma and their courses of treatment provide context for our discussion. Twenty-four (10%) out of 244 trials for women with ovarian carcinoma fit our search terms for maintenance trials. Five (2%) trials studied radiopharmaceuticals as switch maintenance. In our opinion, radiopharmaceutical switch maintenance merits further testing in prospective trials for women with advanced-stage primary platinum recurrent or refractory ovarian carcinoma.


  • Open Access

    Advancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway

    by Kaveh Zakeri, Deepa Narayanan, Greg Evans, Pataje Prasanna, Jeffrey C. Buchsbaum, Bhadrasain Vikram, Jacek Capala

    The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs of the National Cancer Institute (NCI) are congressionally mandated set-aside programs that provide research funding to for-profit small businesses for the development of innovative technologies and treatments that serve the public good. These two programs have an annual budget of $159 million (in 2017) and serve as the NCI’s main engine of innovation for developing and commercializing cancer technologies. In collaboration with the NCI’s Radiation Research Program, the NCI SBIR Development Center published in 2015–2017 three separate requests for proposals from small businesses for the development of systemic targeted radionuclide therapy (TRT) technologies to treat cancer. TRT combines a cytotoxic radioactive isotope with a molecularly targeted agent to produce an anticancer therapy capable of treating local or systemic disease. This article summarizes the NCI SBIR funding solicitations for the development of TRTs and the research proposals funded through them.


  • Open Access

    Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches—Meeting Viewpoint

    by Mansoor M. Ahmed, C. Norman Coleman, Marc Mendonca, Soren Bentzen, Bhadrasain Vikram, Stephen M. Seltzer, Dudley Goodhead, Ceferino Obcemea, Radhe Mohan, Kevin M. Prise, et al.

    The ability to physically target radiotherapy using image-guidance is continually improving with photons and particle therapy that include protons and heavier ions such as carbon. The unit of dose deposited is the gray (Gy); however, particle therapies produce different patterns of ionizations, and


  • How Will Big Data Improve Clinical and Basic Research in Radiation Therapy?

    by Barry S. Rosenstein, Jacek Capala, Jason A. Efstathiou, Jeff Hammerbacher, Sarah L. Kerns, Feng-Ming (Spring) Kong, Harry Ostrer, Fred W. Prior, Bhadrasain Vikram, John Wong, et al.